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Abstract
Background: Nor-BNI, GNTI and JDTic induce κ opioid antagonism that is delayed by hours and can persist for
months. Other effects are transient. It has been proposed that these drugs may be slowly absorbed or distributed,
and may dissolve in cell membranes, thus slowing elimination and prolonging their effects. Recent evidence
suggests, instead, that they induce prolonged desensitization of the κ opioid receptor.
Methods: To evaluate these hypotheses, we measured relevant physicochemical properties of nor-BNI, GNTI and
JDTic, and the timecourse of brain and plasma concentrations in mice after intraperitoneal administration (using LC-
MS-MS).
Results: In each case, plasma levels were maximal within 30 min and declined by >80% within four hours,
correlating well with previously reported transient effects. A strong negative correlation was observed between
plasma levels and the delayed, prolonged timecourse of κ antagonism. Brain levels of nor-BNI and JDTic peaked
within 30 min, but while nor-BNI was largely eliminated within hours, JDTic declined gradually over a week. Brain
uptake of GNTI was too low to measure accurately, and higher doses proved lethal. None of the drugs were highly
lipophilic, showing high water solubility (> 45 mM) and low distribution into octanol (log D7.4 < 2). Brain
homogenate binding was within the range of many shorter-acting drugs (>7% unbound). JDTic showed P-gp-
mediated efflux; nor- BNI and GNTI did not, but their low unbound brain uptake suggests efflux by another
mechanism.
Conclusions: The negative plasma concentration-effect relationship we observed is difficult to reconcile with
simple competitive antagonism, but is consistent with desensitization. The very slow elimination of JDTic from brain
is surprising given that it undergoes active efflux, has modest affinity for homogenate, and has a shorter duration of
action than nor-BNI under these conditions. We propose that this persistence may result from entrapment in
cellular compartments such as lysosomes.
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A growing body of preclinical evidence suggests that se-
lective κ (kappa) opioid antagonists may have thera-
peutic potential against conditions such as depression
and anxiety disorders [1]. However, the drugs used in
this research exhibit an extraordinarily long duration of
action, which has complicated experimental design and
interpretation. The effects of non-selective opioid
antagonists typically persist for only a few hours in vivo;
durations of several days are considered extremely long.
In striking contrast, the effects of selective κ opioid
antagonists can persist for weeks or months [2,3]. A
less-noted peculiarity of their timecourse is extremely
delayed onset; maximal antagonism can be delayed by
hours or days even after central administration, com-
pared to minutes for nonselective antagonists [3]. Re-
cently, short-acting κ opioid antagonists have been
reported, which appear in preliminary experiments to
exert similar effects on stress-related behaviors [4,5].
However, it is as yet unclear whether the abnormal time-
course of the earlier agents is a desirable feature or a li-
ability for clinical development [1]. Additionally, a
consensus has not yet been established on the mechan-
ism of this extremely unusual timecourse.
The first reported highly selective κ opioid antagonist
was norbinaltorphimine (nor-BNI, Figure 1), a dimeric
naltrexone derivative [6]. The compound has become a
standard tool in opioid pharmacology, thoroughly
characterized in a large body of research. In vitro, nor-
BNI reliably produces surmountable antagonism of κ
opioids, with high potency and selectivity over μ (mu)
and δ (delta) opioid receptors [2]. Of the many other se-
lective κ opioid antagonists which have been developed
since [2,7], two have been the subject of considerable
in vivo study: 5’-guanidinonaltrindole (GNTI) [8] and
JDTic [9], both shown in Figure 1. In vitro, these com-
pounds also produce surmountable antagonism of κ
opioids, with sub-nanomolar potency and high selectivity
over μ and δ [2].
Delayed onset
In vivo, nor-BNI can exert selective antagonism of di-
verse κ opioids across numerous assays and species [3].
In these respects, nor-BNI is unremarkable compared to
other selective opioid antagonists. However, the com-
pound’s timecourse is extremely different. Negligible an-
tagonism of κ opioids is evident for 30 minutes after
subcutaneous administration; antagonism then rises
gradually towards a plateau after at least two hours [10].
By contrast, the effects of naltrexone, a non-selective an-
tagonist, peak within 30 minutes, then decline rapidly
[11]. Onset of κ antagonism is markedly delayed even
after central administration of nor-BNI. Whereas the
effects of naloxone peak within 15 minutes of i.c.v. ad-
ministration and decline rapidly [12], nor-BNI again
shows dramatically slower onset, with κ antagonism in-
creasing for at least 4 hours [13]. This delay in onset has
been observed in numerous studies in multiple species
[3]. GNTI and JDTic also show robust and selective an-
tagonism of κ opioids in vivo [3]. Like nor-BNI, maximal
κ antagonism after systemic administration of GNTI is
delayed by several hours [14]; for JDTic, the delay is sub-
stantially greater than six hours after oral administration
[15].
Ultra-long duration of action
These three compounds exhibit an extremely long dur-
ation of action, producing measurable antagonism for
several weeks at minimally-effective doses [2,3]. At
higher doses and by other routes of administration, the
effects of these compounds are further prolonged. This
has been most extensively studied for nor-BNI, which at
high doses has a duration of action of several months in
some species [3,16]. Compare these values to the typical
duration of several hours achieved by the non-selective
opioid antagonists naltrexone and naloxone [11]. Indeed,
these durations are substantially longer even than that of
the irreversible antagonist β-chlornaltrexamine (β-CNA).
This drug binds covalently to opioid receptors, and per-
sists until the receptors themselves are degraded and
replaced, giving what has been described as an “ultra long”
duration of action [17]. At the highest sub-lethal i.c.v.
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Figure 1 Structures of nor-BNI, GNTI, JDTic, and naltrexone.
Drugs are shown in the predominant ionization state at
physiological pH.
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6 days [17]. This duration is greatly exceeded by even
minimally-effective doses of nor-BNI, GNTI and JDTic
[18].
Transient side-effects
Despite its high κ-selectivity in vitro, nor-BNI produces
transient μ antagonism in vivo. The timecourse is strik-
ingly different than at κ, peaking approximately 30 min-
utes after subcutaneous administration and lasting
approximately 4 hours [10]. This is approximately the
same timecourse as naltrexone [11]. GNTI reportedly
does not cause transient μ antagonism [14]; however, it
does cause another transient side-effect, sedation. This is
of rapid onset and lasts several hours [14]. Transient μ
antagonism has not been reported after JDTic [19]; nor
are we aware of other transient side-effects. It should be
noted, however, that less evidence is available for this
compound. That nor-BNI and GNTI induce rapid-onset,
transient side-effects along with delayed and prolonged
κ antagonism is a notable and puzzling characteristic
which has not yet been explained.
Proposed mechanisms
Several mechanisms for the extremely unusual time-
course of these compounds have been proposed, none of
which have won broad acceptance. They can be divided
into two general categories. In the first category, the
timecourse of antagonism is presumed to reflect the
timecourse of the drugs themselves at the effect site. It
has been proposed that the delay in onset of nor-BNI
may be due to the large size of the molecule (compare
naltrexone, Figure 1), or poor membrane permeability,
causing slow diffusion to the site of action [20]. The long
duration of action has been tentatively attributed to dis-
solution in cell membranes, creating a depot from which
the drug would slowly diffuse [13].
The second general category involves irreversible pro-
cesses: that the drugs, while transient themselves, initiate
some process which produces delayed and persistent an-
tagonism. It was speculated that these drugs might in-
duce an abnormal conformation in the receptor,
rendering it inactive [13], initiate a post–receptor event
with a memory [15], or generate an active metabolite
with poor permeability [21]. Recently, the first detailed
investigations of this issue have revealed evidence for an
irreversible mechanism. Specifically, it has been reported
that nor-BNI, GNTI and JDTic activate the enzyme c-
Jun N-terminal kinase 1 (JNK1, MAPK8), which in turn
causes prolonged inhibition of κ signaling [18,22,23].
More recently, it has been reported that κ antagonists
with low efficacy towards JNK1 have short durations of
action [7].
As a contribution to evaluating these mechanisms, we
investigated one of the fundamental questions at issue:
are these drugs in fact slowly absorbed and eliminated?
We administered nor-BNI, GNTI and JDTic to mice at
10 mg kg
-1 i.p., as used in a previous study of their time-
courses [18]. At various timepoints, the mice were sacri-
ficed, and drug levels in brain and plasma were
determined. We also measured physicochemical proper-
ties relevant to disposition and depot formation. Specif-
ically, we measured drug binding to plasma proteins and
brain homogenate. We also measured octanol/water
drug distribution, a standard measure of lipophilicity, at
physiologic pH (7.4). As a further test of lipophilicity or
hydrophobicity, we measured the water solubility of each
compound. Lastly, we performed permeation experi-
ments in cells expressing human permeability glycopro-
tein (P-gp) to evaluate the rates of active transport and
passive diffusion for these compounds across cell
membranes.
Results
Plasma and brain timecourses
Plasma and brain levels of nor-BNI are shown in Figure 2;
raw data for figures and tables can be found in Additional
file 1. Mean plasma nor-BNI was maximal at 30 minutes,
then declined significantly within 1 hour (56%, p=0.04).
The decline was almost complete within 2 hours (92%).
After this, there was a reduction in the elimination rate
(see Figure 2B), with an eventual decline of 99% by 24
hours.
Brain uptake of nor-BNI was very low. Standard LC-
MS-MS conditions gave lower sensitivity in brain than
for a wide range of drugs tested previously [24]. As a re-
sult, we obtained accurate brain levels for nor-BNI only
up to 1 hour. Nonetheless, no lag was apparent, indicat-
ing rapid equilibration between blood and brain. Mean
brain nor-BNI was maximal at 30 minutes, and declined
significantly within 1 hour (31%, p =0.03). By 2 hours, 2
of 3 samples were below the Minimum Reportable Con-
centration (MRC) for our assay (120 ng mL
-1). This per-
mits only an estimate of the initial elimination rate,
which is often much higher than the terminal elimin-
ation rate. Thus, our data do not establish the terminal
elimination rate in brain.
Absorption and elimination of GNTI were somewhat
slower (Figure 3). Again however, mean plasma levels
were maximal at 30 minutes, and declined by 95%
within 4 hours (p =0.01). Viewed on a log scale there
was again a marked decline in the elimination rate after
4 hours (Figure 3B). Brain uptake was extremely low.
Levels were below MRC (120 ng mL
-1) at all timepoints,
and thus could not be accurately quantified, so the time-
course in brain could not be determined.
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absorbed, reaching peak plasma and brain levels within
approximately 30 minutes (Figure 4). Mean plasma con-
centration declined by 37% within 1 hour (p=0. 04 ),an d
77% within 2 hours (p=0.003). Brain levels were markedly
lower than plasma, but the drug was very persistent: mean
brain JDTic declined by only 56% over 24 hours, and the
drug was still detectable at 1 week (Figure 4B). The ter-
minal half-life of approximately 9 days was comparable to
the previously reported rate of decline in antagonism [18].
The possibility remains that nor-BNI also persists at
lower levels, below our MRC. There have been prelimin-
ary reports of the detection of nor-BNI in mouse brain up
to 21 days after administration, but details have not yet
been reported [25,26]. Nonetheless, our results indicate
that the initial elimination rate from brain for nor-BNI is
much higher than for JDTic, with brain levels declining by
at least 75% within 4 hours. Our results do not permit
conclusions about the brain timecourse of GNTI.
Physicochemical properties
We found that nor-BNI, as the standard salt (dihy-
drochloride hydrate), showed poor wettability and
dissolved slowly. This property may have contributed to
the perception that the drug is hydrophobic. In fact, how-
ever, solubility was very high: greater than 45 mM for
nor-BNI and JDTic, and at least 100 mM for GNTI
(Table 1). These values are comparable to the short-act-
ing antagonist naltrexone. By contrast, some lipophilic
drugs such as steroids have solubilities below 1 μM, at
least 10
5-fold lower than GNTI [27]. Notably, all of the κ
antagonists crystallize as hydrates, whereas most drug
salts crystallize as anhydrates [28]. Thus, as measured by
both solubility and degree of hydration, the κ antagonists
are unusually hydrophilic.
The octanol/water distribution coefficient at physio-
logical pH (log D7.4), a standard measure of lipophilicity
for ionizable compounds, provides further evidence that
these drugs are not unusually hydrophobic (Table 1).
While more hydrophobic than naltrexone, nor-BNI and
JDTic nonetheless fell within the moderate log D7.4
range of 1–3, which is optimal for a wide range of
pharmacological properties [29]. To put this in context,
the short-acting cannabinoid THC has a reported log
D7.4 value of 7 (10
5–fold more lipophilic than JDTic)
[30]. Interestingly, GNTI proved to be very hydrophilic,
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Figure 2 Nor-BNI levels in plasma and brain in mice over 24 hours (10 mg kg
-1i.p.). A, linear scale with inset of brain levels; B, log scale
[×=MRC÷2 (estimate for points<MRC)].
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Thus, none of the κ antagonists possessed exceptionally
high or low lipophilicity, and they differ more from each
other by these measures than from naltrexone.
Brain homogenate and plasma binding
We measured drug binding to plasma proteins and brain
homogenate, since it is the concentration of unbound
drug in solution, rather than total concentration, which
governs pharmacological response [32]; also, affinity for
brain homogenate provides an experimental test of the
membrane depot hypothesis. Each κ antagonist showed
greater binding to brain homogenate than did naltrex-
one, with unbound fractions below 12% (Table 1). How-
ever, these values are not exceptional: some CNS-active
drugs exhibit unbound fractions below 0.1% in brain
homogenate [33].
Recent work indicates that homogenate binding sys-
tematically underestimates binding to intact tissue by
approximately 3-fold for basic drugs [34]. For theoretical
reasons discussed below, the underestimate is expected
to be substantially greater for dibasic compounds like
the long-acting κ antagonists (Figure 1) [34]. However,
since validated results for a set of dibasic drugs are not
available, in the calculations that follow we have conser-
vatively assumed in vivo brain binding at least 3-fold
greater than the homogenate value.
Brain uptake
A common measure of brain uptake is Kp,brain, or drug
exposure in brain relative to plasma. However, Kp,brain
values do not accurately predict drug concentrations at
the effect site, since they are confounded by tissue and
plasma binding [34]. After correction for binding, the
relative unbound brain/plasma exposure (Kp,uu,brain)
gives a much more accurate guide to drug levels in inter-
stitial fluid, as validated against microdialysis [34].
Nor-BNI’s unbound brain/plasma exposure (Kp,uu,brain)
was extraordinarily low, less than 0.007 (see Table 2).
This is comparable to the peripherally-restricted opioid
loperamide [35]. While surprising for a centrally-active
drug, this value is consistent with the discrepancy
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http://www.biomedcentral.com/1471-2210/12/5between the extremely high potency nor-BNI exhibits
in vitro [2] and its low potency in vivo.
Unbound brain exposure for JDTic was much greater
than for nor-BNI, up to a possible upper bound of 1.4
(Table 2). This was puzzling given the low peak brain
level of JDTic. As an alternate measure, we calculated
unbound brain uptake using peak brain and plasma
levels. By this measure, unbound uptake of JDTic was
very low, < 0.04, in marked contrast to the exposure
measure. For nor-BNI, the two methods gave concordant
results. Calculations based on exposure may be mislead-
ing for JDTic due to the extraordinarily large difference
in elimination rates between brain and plasma. Compari-
son of drug concentrations in brain and plasma clearly
establishes low unbound uptake for this drug. Further
evidence on this question can be found in the results of
our active transport experiments below.
Brain exposure could not be quantified for GNTI at
10 mg kg
-1. In an attempt to obtain quantifiable brain
levels we administered higher doses, which unexpectedly
proved lethal, as described in the next section. At 10–18
minutes after GNTI bis-trifluoroacetate (39 mg kg
-1),
postmortem brain and plasma samples revealed a very
high mean plasma concentration of 13,200 ng mL
-1, but
a mean brain level (112 ng mL
-1) still just below the
MRC (120 ng mL
-1). It should be noted that the low
brain levels at this early timepoint may reflect incom-
plete equilibration. Nonetheless, GNTI clearly exhibited
extremely low brain uptake in all of these experiments.
Even these very low uptake values represent conserva-
tive upper bounds, and the true values are likely to be
lower still. We have chosen a minimal value for the
underestimate of tissue binding using homogenate, as
noted above, and the true binding is likely to be greater.
Also, we have not corrected for residual plasma in brain.
The brain is estimated to contain approximately 1–3%
blood by volume, which can make a substantial contribu-
tion to total brain drug content for drugs with low up-
take [32]. However, correction for this is complex, and
to our knowledge the required parameters have not yet
been established in mice. This correction would further
reduce the estimated brain uptake. Consistent with this,
note that we estimate peak unbound brain levels at 30
minutes of up to 4 nM for JDTic and 26 nM for nor-BNI
(Table 2). Given that the binding affinities and potencies
of these drugs in vitro are consistently sub-nanomolar
[2], these concentrations would be expected to produce
near-maximal receptor occupancy, and marked increases
in the ED50 of κ opioids. As noted above, however, negli-
gible κ antagonism is observed at 30 minutes (Figure 5).
This suggests that the true unbound brain concentra-
tions are considerably lower.
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acting κ antagonists exhibit extremely low brain uptake
relative to other centrally-active drugs, but accurate
quantification will require further research.
Fatalities after GNTI
After 30 mg kg
-1 GNTI dihydrochloride, all three mice
unexpectedly became ataxic, followed by convulsions
and death within 11 minutes of injection. To confirm
that this was not due to an impurity, the experiment was
repeated with an equimolar dose of a different salt from
a different supplier (bis-trifluoroacetate, 39 mg kg
-1).
Again, all three mice died within 18 minutes. At
10 mg kg
-1, GNTI caused no fatalities in 15 mice moni-
tored for at least 30 minutes. This difference was of
extremely high statistical significance (p< 0.0001 by
Fisher’s Exact test, two tailed). Even at 100 mg kg
-1,n o
fatalities occurred after nor-BNI (3 mice, p =0.01 vs.
GNTI) or JDTic (6 mice, p =0.002). Only mild behav-
ioral effects, such as hiccup-like spasms and shivering,
were observed. The lower toxicity of these two drugs,
despite their comparable potency as κ antagonists,
suggests that GNTI's toxicity may involve some form of
efficacy or a different target.
Apparent volume of distribution
In addition to the direct tests of binding to plasma and
brain homogenate, our results yield an indirect measure
of tissue affinity. It is notable that at the same dose,
JDTic gave maximal plasma concentrations less than
10% of those seen after nor-BNI and GNTI (Table 2).
This might reflect lower absorption into plasma, higher
affinity for tissue relative to plasma, or both. This prop-
erty can be quantified using the volume of distribution
(V).
Based on the above timecourse and binding data,
pharmacokinetic parameters were calculated using non-
compartmental analysis (Table 2). Apparent terminal-
phase volumes of distribution (Vz/F) f o rG N T I( 4 . 4Lk g
-1)
and nor-BNI (19 Lkg
-1) were unremarkable in comparison
to the values of V for a wide range of other drugs deter-
mined previously in rats (0.1 – 73 L kg
-1) [24]. The
volumes of distribution for GNTI and nor-BNI therefore
appear to be low or moderate relative to other CNS-
targeted drugs, suggesting moderate tissue affinity
relative to plasma. This is consistent with the brain
homogenate binding we observed.
Table 1 Physicochemical properties and plasma and brain
homogenate binding of nor-BNI, GNTI, JDTic, and
naltrexone
Nor-BNI GNTI JDTic Naltrexone
Salt tested 2HCl·H2O 2HCl·1.5H2O 2HCl·H2O HCl·2H2O
Water solubility
(mmol L
-1, 25 °C)
>45 >100
a >45 >100
a
mean
(95% CI)
Log10D7.4 1.5 -0.1 1.8 0.86
octanol:buffer (pH 7.4) (1.3; 1.8) (-0.2; 0) (1.7; 2.0) (0.82; 0.90)
Fraction unbound (%)
Plasma 51 28 19 83
(44; 59) (24; 31) (17; 21) (72; 94)
Brain homogenate 12 7 74 7
(10; 17) (6; 9) (6; 8) (34; 65)
Experiments performed in triplicate (n = 3).
a)Tocris product information sheet.
Table 2 Pharmacokinetic parameters of nor-BNI, GNTI and JDTic (·2HCl salts, 10 mg kg
-1 i.p.), estimated using non-
compartmental analysis
Nor-BNI GNTI JDTic
tmax h 0.5 0.5 0.5
Cmax,p ng mL
-1 4,025 3,080 245
Cmax,brain ng mL
-1 443 < 120 71
Cmax,brain,u nmol L
-1 < 26 < 6 < 4
AUC0–∞,p ng hmL
-1 6,422 9,486 888
AUC0–∞,brain ng hmL
-1 593 - 10,304
Vz/F Lk g
-1 19 4.4 83
CL/F Lk g
-1 h
-1 1.7 1.0 1.1
AUC0–∞,brain/AUC0–∞,p Kp,brain 0.09 – 11.6
AUC0–∞,brain,u/AUC0–∞,p,u Kp,uu,brain < 0.007 – < 1.4
Cmax,brain/Cmax,p 0.11 0.0085
a 0.29
Cmax,brain,u/Cmax,p,u < 0.009 < 0.0007
a < 0.04
a) From postmortem samples, 13–18 minutes after 39 mg kg
-1 GNTI·2CF3CO2H.
Abbrevations: AUC, area under curve; CL, clearance; Cmax, maximal mean concentration; F, bioavailability; p, plasma; tmax, time at Cmax; u, unbound (free); Vz,
terminal-phase apparent volume of distribution.
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JDTic was extremely high (83 L kg
-1). While this might
be due to low bioavailability (F), it is also consistent with
a very high value for V – that is, very high affinity for
tissue relative to plasma. JDTic’s negligible rate of elim-
ination from brain, but not plasma, provides strong con-
firmation of high tissue affinity. This is in marked
contrast to the compound's moderate affinity for brain
homogenate. Given that membranes do not represent a
plausible basis for this affinity, we propose an alternative
in the discussion section.
Membrane permeation and efflux
The membrane permeabilities of these drugs were evalu-
ated using monolayers of cells expressing human P-gp.
All three of the long-acting antagonists showed
extremely low passive permeability, up to 150-fold lower
than naltrexone, as measured by apical to basolateral
flow rates (Table 3). No active transport of nor-BNI or
GNTI was detectable, but JDTic showed a very high
efflux ratio. Consistent with previous reports [36], the
known P-gp substrate loperamide also showed high
efflux, but naltrexone did not. These results suggest that
JDTic is a P-gp substrate, but that nor-BNI and GNTI
are not.
Discussion
Absorption rate and transient side effects
As noted above, nor-BNI plasma levels peaked early and
declined rapidly. Interestingly, as seen in Figure 5, the
reported timecourse of μ antagonism fits this plasma
timecourse closely. The rise in κ antagonism is diamet-
rically opposed to the decline of plasma levels between
Table 3 Mean permeation rates and efflux ratios in LLC-
PK1-MDR1 cell monolayers
Nor-BNIGNTIJDTicNaltrexoneLoperamide
Papp (A→B) nm s
-1 2 4 5 310 12
Papp (B→A) nm s
-1 3 6 240 410 470
Efflux ratio (B→A/A→B) 1.5 1.5 48 1.3 38
A= apical, B= basolateral. Experiments performed in duplicate (n= 2).
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-1s.c., mice [10]); B, nor-BNI
plasma levels and mean area under curve (AUC) over the same period.
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http://www.biomedcentral.com/1471-2210/12/530 minutes and 4 hours. Interestingly, however, a close
correspondence is apparent to cumulative exposure (area
under curve, AUC). Both κ antagonism and AUC exhibit
a low initial rate of increase when drug level is low, a
maximal rate of increase at ~30 minutes when drug level
peaks, then a gradual taper to a plateau as the drug is
eliminated. It should be noted that these antagonism
data were obtained after subcutaneous rather than intra-
peritoneal administration. Nonetheless, these routes give
very similar absorption rates: analgesia peaks 15–30
minutes after administration of morphine to mice by
either i.p. [37] or s.c. routes [38]. The striking
01234
0.1
0.2
0.3 plasma [GNTI]
κ antagonism
100
1,000
[
G
N
T
I
]
 
(
n
g
 
m
L
-
1
)
02468 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
10
100
Time after antagonist (hour)
[
J
D
T
i
c
]
 
(
n
g
 
m
L
-
1
)
plasma [JDTic]
AUC
0
20
40
60
80
 
A
n
t
a
g
o
n
i
s
m
 
(
%
)
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
E
D
5
0
 
o
f
 
U
5
0
,
4
8
8
H
 
(
m
g
 
k
g
-
1
)
A
U
C
 
(
n
g
 
h
 
m
L
-
1
)
AUC C
0
200
400
600
800
1,000
A
U
C
 
(
n
g
 
h
 
m
L
-
1
)
κ antagonism antagonism
A
B
Figure 6 Early mean plasma levels and AUC compared to the reported timecourses of κ antagonism for GNTI (A: rhesus monkeys,
1m gk g
-1 i.m. [14]) and JDTic (B: mice, i.g. [15]).
0 1 7 1 42 12 8
5
4
3
2
concentrations
(←left axis) [GNTI]
plasma
 
L
a
t
e
n
c
y
 
a
f
t
e
r
 
U
5
0
,
4
8
8
H
 
(
s
e
c
)
Time after antagonist (days)
GNTI
antagonism
Saline
0.1
1
10
100
C
t
/
C
m
a
/
C
/
C
x
 
(
%
)
JDTic
antagonism
[JDTic]
brain
[JDTic]
plasma
[Nor-BNI]
plasma Nor-BNI
antagonism
(right axis→)
κ antagonism
[Nor-BNI]brain
Figure 7 Elimination of nor-BNI, GNTI and JDTic from brain and plasma compared to the reported durations of κ antagonism at the
same dose (mean±95% CI, 10 mg kg
-1 i.p. in mice, tail flick assay [18]).
Munro et al. BMC Pharmacology 2012, 12:5 Page 9 of 18
http://www.biomedcentral.com/1471-2210/12/5correspondence between plasma concentrations and μ
antagonism in Figure 5 suggests that the same is true of
nor-BNI.
The same pattern is evident for GNTI in Figure 6A.
As noted in the Background section, GNTI induces
transient sedation. In mice (i.p.), sedation was maximal
within 20 minutes and lasted less than 3 hours [39]; in
rhesus monkeys (i.m.), rapid onset and a duration of
“several hours” was reported [14]. Thus, despite the dif-
ferent routes of administration, the timecourse of that
effect in both species closely approximates the plasma
timecourse observed here. A close resemblance is also
evident again between the delayed onset of κ antagonism
and our cumulative AUC data.
As with GNTI, JDTic reportedly does not cause transi-
ent antagonism of μ opioids [19]; nor are we aware of
any reports of other transient side-effects. However, a
close correspondence between the onset of κ antagonism
and AUC is again apparent (Figure 6). Notably, due to
the slower elimination of JDTic compared to nor-BNI
and GNTI, the rise in AUC was much slower, matching
the much slower onset of antagonism.
These antagonism data were obtained after intragastric
(i.g.) administration of JDTic, which may delay absorption
compared to the intraperitoneal route we employed.
However, absorption after i.g. administration in rodents is
typically rapid. Drugs with diverse absorption rates
in vitro attain peak plasma levels 15–45 minutes after i.g.
administration to rats [40]. Similarly, the effects of opioid
antagonists including naloxone and naltrexone are
maximal, or non-significantly below maximal, within 30
minutes of i.g. administration in mice [41] and rats [42].
Maximal analgesia after i.g. morphine is delayed by 30
minutes or less compared to i.p. administration [37].
Thus, intragastric administration cannot plausibly account
for the delay in onset of JDTic, which is substantially
greater than 6 hours (Figure 6B). Furthermore, JDTic
exhibits equally slow onset after subcutaneous administra-
tion in rats [15]. At equal doses, the effects of nor-BNI
were equal to, or greater than, those of JDTic over the first
five hours. But after a week, JDTic's effects had substan-
tially increased, while those of nor-BNI were unchanged
or reduced, leaving JDTic consistently more effective [15].
This confirms that maximal κ antagonism after JDTic is
delayed by at least several hours compared to nor- BNI,
despite the equally rapid absorption we observed.
Elimination rate and duration of action
Plasma levels of nor-BNI, GNTI, and JDTic declined rap-
idly, with mean concentration falling at least 80% below
0
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Figure 8 Concentration-effect relationships derived from Figures 5 and 6. A: Plasma nor-BNI concentrations against reported μ and κ
antagonism at the indicated times (mice, 20 mg kg
−1 s.c. [10]). B: Plasma and brain JDTic concentrations against reported κ antagonism (mice, i.g. [15]).
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http://www.biomedcentral.com/1471-2210/12/5peak within 4 hours in all cases, and at least 98% below
peak at 24 hours. By contrast, reported κ antagonism is
still maximal at 48 hours, and declines gradually over 3–
4 weeks at the same dose (Figure 7). However, plasma
levels do not always accurately predict concentrations in
the brain. For instance, plasma levels of haloperidol in rats
decline rapidly (undetectable within 2 days), while brain
concentration takes 3 weeks to reach the same level, cor-
responding closely to the decline in antagonism [43]. Our
data do not establish the rate of elimination from brain for
GNTI, but indicate rapid initial elimination for nor-BNI
(in contrast to the long duration of antagonism).
For JDTic, however, the rates of decline in brain concen-
tration and antagonism were comparable. Thus, it would
seem more plausible to attribute JDTic’s long duration of
action to persistence of the drug in brain than for nor-BNI
and GNTI. This will be discussed further below. It is im-
portant to note, however, that this proposal leaves delayed
onset unexplained. Indeed, the lag (or hysteresis) between
peak drug level and peak antagonism is many hours
longer for JDTic than nor-BNI and GNTI (compare
Figures 5 and 6). A common and intuitive way to analyze
hysteresis is to plot drug concentration versus effect over
time. In Figure 8, our concentration data for nor-BNI and
JDTic are plotted against the previously reported antagon-
ism data from Figures 5 and 6.
Competitive, reversible drug effects show a sigmoidal
relationship with drug concentration in vitro. In vivo,
opioids with diverse physicochemical properties and
pharmacokinetic parameters show sigmoidal brain
concentration-effect relationships [37,38]. As seen in
Figure 8A, plasma levels of nor-BNI exhibit a strong
sigmoidal relationship with μ antagonism, consistent with
such a competitive, reversible mechanism of action.
Drugs with slow blood–brain equilibration show a
weaker correlation, with the points forming a ‘hysteresis
loop’ [37,38], but a strong positive correlation remains be-
tween concentration and effect. By contrast, the correl-
ation between plasma [nor-BNI] and κ antagonism is
strongly negative; that is, maximal plasma concentrations
coincide with minimal antagonism and vice versa. Brain
concentrations have not been plotted due to the small
number of points available, but the same discrepancy is
apparent in Figure 2. For JDTic, plasma concentration and
κ antagonism were also negatively correlated (Figure 8B).
Despite slower elimination from brain, the correlation
with brain concentration was also negative. There were in-
sufficient common timepoints available to plot a similar
curve for GNTI, but it is evident from Figures 6 and 7 that
t h es a m en e g a t i v ec o r r e l a t i o nh o l d s .
Resemblance to irreversible antagonists
Thus, for all three of these drugs there is a strongly
negative correlation between concentration and κ
antagonism over most of the timecourse, unlike the
positive correlation characteristic of reversible, competi-
tive drug action. Similar discrepancies are seen with
irreversible antagonists. For example, β-funaltrexamine
(β-FNA) binds covalently to the μ opioid receptor, as
recently confirmed by crystal structure [45]. This results
in prolonged μ antagonism in vivo [45], which can
exhibit delayed onset both in vitro [46] and in vivo [47].
However, β-FNA is also a reversible κ agonist, and
unlike μ antagonism this effect is of rapid onset and
brief duration in vivo [45].
While reversible effects are a function of drug concen-
tration, irreversible effects persist after the drug is
washed out [48]: they are thus a function of prior expos-
ure rather than concentration. As a corollary to this,
irreversible effects continue to rise as long as drug and
substrate are present, resulting in delayed onset [48].
This severe hysteresis in the concentration-effect rela-
tionship, where maximal effect can coincide with
minimal concentration and vice versa, is a noteworthy
similarity between the long-acting κ antagonists and
irreversible antagonists. The occurrence of transient
side-effects is another striking similarity between β-
FNA, nor-BNI and GNTI.
There are also important differences, however. Nor-
BNI, GNTI, and JDTic all bind reversibly in vitro, and
lack reactive functionalities capable of forming a covalent
bond to the receptor [2]. For JDTic, this has recently
been definitively confirmed by the crystal structure in
complex with the κ opioid receptor [49]. Consistent with
this, all three drugs produce surmountable antagonism
[2,3]. Insurmountable antagonism (a reduction in max-
imal response to agonists) is a defining characteristic of
irreversible antagonists. It is important to note, however,
that insurmountable antagonism is not always observed
– in systems with high receptor reserve, irreversible
antagonists can produce surmountable antagonism [50].
Resemblance to agonist-induced desensitization
The hysteresis typical of irreversible drugs is also seen
when drugs bind reversibly, but induce irreversible
effects. Daily doses of the κ opioid U50,488H induce tol-
erance, such that doses which initially produced near-
maximal analgesia are without effect by the fifth day
[51]. This desensitization is believed to be mediated by
phosphorylation of the receptor: while the drug itself
binds reversibly, it promotes a covalent modification
which inhibits signaling. This process shares some of the
characteristics of an irreversible antagonist, notably a
very long duration (two weeks after moderate doses of
U50,488H) [51], and slow onset. Due to the very slow
rate of resensitization, the process is cumulative, and
rises with each dose rather than falling with plasma drug
levels, resulting in gradual onset over several days. By
Munro et al. BMC Pharmacology 2012, 12:5 Page 11 of 18
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gesia and sedation) are of rapid onset and brief duration.
As with irreversible antagonists, desensitization may
cause insurmountable antagonism, but this is not always
observed [50]. Repeated administration of κ opioids can
produce either surmountable or insurmountable
desensitization [52]. Similarly, desensitization may re-
duce maximal binding (Bmax) of radioligands, rather than
affinity (Kd), but the opposite effect has also been
reported, depending on experimental conditions [52].
Explanation of hysteresis by JNK-mediated
desensitization
Our results are consistent with recent reports that long-
acting κ antagonists activate c-Jun N-terminal kinase 1
(JNK1), which in turn inhibits signaling [18,22]. As noted
above, resensitization at κ is very slow, and JNK1-mediated
desensitization might therefore be expected to be long-
lasting. Since persistent desensitization will be cumulative,
we propose that it may display delayed onset, as with agon-
ist-induced desensitization and irreversible antagonism.
Specific mechanisms for the observed transient side
effects have not yet been proposed. However, any revers-
ible effects of the drugs would be expected to be a func-
tion of drug levels, as seen with β-FNA. The effects
might result from reversible interactions with other tar-
gets, or from reversible effects upon specific κ signaling
pathways. The JNK1 hypothesis thus provides a parsimo-
nious explanation for the occurrence of both delayed,
prolonged antagonism and rapid, transient side-effects.
However, our finding that JDTic is much more slowly
eliminated than nor-BNI from brain is more difficult to
explain by this hypothesis, given their similar durations
of action. If both compounds induce prolonged
desensitization, the continued presence of JDTic in
brain would be expected to continue activating JNK1,
resulting in a longer duration of action. One explan-
ation could be desensitization of the JNK1 pathway
itself.
It was recently found that when nor-BNI was adminis-
tered twice over 72 hours, only the first dose activated
JNK1 [7]. Alternatively, total brain content of JDTic
may not accurately reflect unbound drug levels at the
receptor. This would be the case, for instance, if the
drug is sequestered within cells, a possibility discussed
below.
Explanation by formation of active metabolites
Another proposed mechanism for nor-BNI‘sd u r a t i o no f
action was the generation of active metabolites with
poor permeability, which would therefore persist in the
brain [21]. While this hypothesis cannot be excluded
using our results, it would require potent metabolites
with much slower elimination than the parent drug in
each case. However, opioid metabolites are overwhelm-
ingly inactive or less potent than the parent compound,
and rapidly eliminated [53]. Moreover, this hypothesis
does not account for the delayed onset of κ antagonism,
and thus leaves a key aspect of the overall hysteresis un-
accounted for.
Figure 9 Structures of nor-BNI, short-acting κ antagonists and dynorphin A, to the same scale.
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(D-trp)CJ-15,208Explanation by slow absorption and distribution
Contrary to early proposals that nor-BNI might enter
the brain slowly due to poor membrane permeability
[20], plasma and brain levels of all three drugs were
maximal at the first timepoint tested (30 minutes). This
is typical: drugs with a wide range of physicochemical
properties, including those with poor permeability or
low uptake, typically show very little lag between peak
blood and brain levels [38].
Moreover, nor-BNI exhibits delayed onset even after i.c.v.
administration, when permeation of the blood–brain
barrier is not required. To account for this, it was specu-
lated that the bulkiness of the dimeric drug (relative to the
monomer naltrexone) might result in slow diffusion to the
site of action [20]. However, the endogenous κ opioid
dynorphin A is much larger than nor-BNI (Figure 9), yet
exhibits rapid onset after i.c.v. administration, with peak
effects in under 15 minutes [54]. Also shown in Figure 9 is
zyklophin, recently reported to cause κ antagonism of rapid
onset and short duration [5]. Zyklophin is also much larger
than nor-BNI. Other new short-acting κ antagonists are
shown in Figure 9: CJ-15,208 is of comparable size to nor-
BNI [55], while MTAB is smaller [4]. Since both larger and
smaller κ ligands exhibit rapid onset, nor-BNI’s delayed
onset cannot be convincingly explained by its size.
Proposals based upon slow absorption and distribution
also fail to account for the conflicting timecourses of the
transient effects and κ antagonism noted above. If the
delayed onset and long duration of κ antagonism were
due to slow uptake and elimination, transient effects of
rapid onset and brief duration would not be expected.
Explanation by membrane depot formation
It has been proposed that nor-BNI’s long duration of ac-
tion might result from dissolution in cell membranes,
creating a depot from which the drug would slowly dif-
fuse, maintaining drug levels at the receptor [13]. How-
ever, the assumption that any of these drugs is highly
lipophilic is unsupported by theory or evidence. For each
of these drugs, the predominant species at physiologic
pH is doubly charged (Figure 1 and Table 1), with nu-
merous hydrogen bond donors and acceptors, features
which increase hydrophilicity. Consistent with this, all
three drugs exhibit high water solubility, and an un-
usually strong tendency to crystallize as hydrates. Also
consistent with this, JDTic binds to the κ opioid receptor
via a network of eight hydrogen bonds, involving five
water molecules [49].
The octanol/water distribution values of nor-BNI and
JDTic are only moderately lipophilic, while GNTI is very
hydrophilic. Thus, the κ antagonists are not highly lipo-
philic by any of the measures we examined, and in fact
are unusually hydrophilic by several measures. These
data do not support the hypothesis that these drugs
would show a stronger tendency than other opioids to
accumulate in cell membranes or other lipids. The mod-
erate brain homogenate binding we observed provides
further evidence that these drugs do not bind strongly to
cell membranes, or indeed to any other cellular
component.
A second assumption of this hypothesis, that a mem-
brane depot would replenish effective drug levels at the
receptor for weeks or months, is also questionable. (D-
trp)CJ-15,208 is neutral (Figure 9), and so hydrophobic
that a 50% DMSO vehicle was required for injection, but
nonetheless has a duration of action under 24 hours
[55]. THC is extremely lipophilic, with correspondingly
high affinity for membranes [30], but has an even
shorter duration of action.
The depot hypothesis has been tested experimentally:
Bruchas et al. reported that pre-administration of the
rapidly-eliminated antagonist naloxone (30 mg kg
-1 i.p.)
blocked the effects of nor-BNI on subsequent days, sug-
gesting that nor-BNI does not persist at effective levels
longer than naloxone [18]. Paronis et al. did not observe
such protection by naltrexone, but the drugs were given
by different routes of administration [21].
Subcutaneous naltrexone may not have produced suf-
ficient central levels to counteract intra-cisternal nor-
BNI. Also, the dose of naltrexone used (10 mg/kg) may
have been insufficient. As noted there, even very high
doses of competitive antagonists (100 mg kg
-1 naloxone)
do not achieve full protection against irreversible
antagonists [21], and the same may conceivably be true
for irreversible effects of competitive drugs.
JDTic may accumulate in lysosomes
JDTic’s high apparent volume of distribution, and slow
elimination from brain, suggest very high tissue affinity.
The decline in the plasma elimination rate after 4 hours
also suggests a non-plasma compartment with slow
elimination. However, the above evidence indicates mod-
erate affinity not only for membranes, but for all compo-
nents of brain homogenate. Thus, JDTic's tissue affinity
appears to depend upon membrane integrity. Also, given
its extraordinary persistence in brain despite P-gp-
mediated efflux, the drug appears to be isolated from the
extracellular fluid and blood–brain barrier. Taken to-
gether, this evidence suggests sequestration of JDTic
within cells.
One common mechanism for sequestration of basic
compounds is trapping within acidic compartments of
the cell (lysosomes). Acidic conditions protonate basic
compounds, and the resulting charged species is less
membrane-permeable. Membrane-permeable basic drugs
therefore enter lysosomes more readily than they leave,
and become trapped [56]. On average, basic drugs show
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for homogenate [34]. Acidic drugs show a slight bias in
the opposite direction. The discrepancy is not seen for
neutral drugs, and can be abolished by inhibiting lyso-
somal uptake [34]. The compounds which accumulate to
the greatest degree are dibasic, especially when both
bases are weak (pKa ~8): the double protonation results
in a much greater reduction in permeability [56].
JDTic features two weak bases and optimal lipophili-
city for membrane permeation (Figure 1 and Table 1).
JDTic might therefore be expected to accumulate in
lysosomes on theoretical grounds. This would reconcile
JDTic’s apparently high affinity for intact tissue with its
low affinity for homogenate, since lysosomal trapping
requires membrane integrity. While we have no direct
evidence for this, an analogy can be made with the opi-
oid desmethyl-loperamide, whose pharmacokinetic pro-
file is strikingly similar to that of JDTic [57]. Despite
very low brain uptake and rapid clearance from plasma,
the drug is very persistent in brain, from which it cannot
be displaced by opioid antagonists. Desmethyl-lopera-
mide’s low brain uptake is due to P-gp efflux, while its
ultra-low brain elimination rate and high tissue affinity
are due to lysosomal trapping [57]. This drug thus shows
many similarities to JDTic, supporting the conclusions
that JDTic is also a P-gp substrate which is subject to
lysosomal trapping.
Like JDTic, nor-BNI features two weak bases and opti-
mal lipophilicity, and would therefore also be expected
to accumulate in lysosomes (Figure 1 and Table 1). Sur-
prisingly, however, we found no evidence for this: nor-
BNI showed a lower apparent volume of distribution,
and a much higher initial elimination rate from brain.
However, the drug may persist below our minimum re-
portable concentration, and the decline in elimination
rate after 2 hours is again consistent with slow elimin-
ation from a non-plasma compartment. As noted above,
there have been preliminary reports of the detection of
nor-BNI in mouse brain up to 21 days after administra-
tion [25,26]. Given the moderate affinity we observed for
brain homogenate, this would again be consistent with
lysosomal trapping, but not accumulation in cell mem-
branes. GNTI exhibits much lower lipophilicity, and fea-
tures one weak base along with a strongly basic
guanidino group, whose protonation state does not vary
appreciably within the physiological pH range (Figure 1).
GNTI would therefore be expected to show a smaller
decrease in permeability within lysosomes; and indeed,
GNTI’s low apparent volume of distribution is consistent
with lower tissue affinity than JDTic.
Not all of our evidence supports this hypothesis unam-
biguously. The very low passive permeability each of
these drugs exhibits in vitro (Table 3) suggests poor
membrane permeability, which would reduce lysosomal
accumulation. However, lyososomal trapping can reduce
apparent permeability in these experiments [58], so add-
itional sources of evidence would be needed to resolve
this question.
Interestingly, a number of short-acting κ antagonists
have been reported recently, none of which are dibasic
(Figure 9). CJ-15,208 is neutral [55], while MTAB and
others are monobasic [4]. The peptide zyklophin [5] fea-
tures five strongly basic residues. Thus, these com-
pounds would be expected to accumulate to a much
lower degree in lysosomes, or not at all. The correlation
is not perfect: recent work has revealed three dibasic
JDTic analogues with short durations of action [7].
Nonetheless, given that all firmly established long-acting
κ antagonists to date are dibasic, this remains an intri-
guing topic for further research.
Active transport and brain uptake
Our in vitro permeation results, discussed above, indi-
cate that JDTic is a P-gp substrate, with active efflux
comparable to peripherally-restricted opioids. This is
consistent with the low brain uptake we determined.
Our results are also consistent with recent preliminary
results indicating extremely low unbound brain uptake
of nor-BNI and JDTic in rats [4]. In that study, low up-
take of nor-BNI was confirmed by brain microdialysis,
which is not confounded by plasma drug content.
Nor-BNI and GNTI did not act as substrates of
human P-gp in our in vitro assays. Nonetheless, both of
these drugs exhibited even lower unbound brain uptake
than JDTic, which suggests that they are also subject to
active efflux in mouse brain. This discrepancy might re-
flect differences between human and mouse P-gp
(MDR-1a). Alternatively, these drugs may be substrates
for another of the many transporters expressed at the
blood–brain barrier [59].
Questions for future research
For future work, a number of interesting questions re-
main unresolved, and other new questions are raised by
these results. A more sensitive analytical method could
establish whether nor-BNI and GNTI persist in brain at
low concentrations, but would not distinguish bound
from unbound drug. This problem could be overcome
by the use of in vivo brain microdialysis, which would
give the timecourses in extracellular fluid, unconfounded
by plasma levels or tissue binding. Intracellular trapping
could be evaluated by comparing drug binding in brain
slices versus homogenate, which would also allow evalu-
ation of lysosomal uptake and other mechanisms [34]. If
tissue uptake could be reduced, for instance by inhibit-
ing lysosomal uptake, the effect on the drugs’ timecourse
in vivo would be informative. A clear understanding of
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as members of this class advance toward the clinic.
Conclusions
Contrary to previous speculations, nor-BNI, GNTI and
JDTic were rapidly absorbed and eliminated from
plasma after intraperitoneal administration. This time-
course is in striking contrast to the slow onset and ultra-
long duration of the κ antagonism they produce, but
coincides well with transient side-effects. Thus, the tran-
sient effects are positively correlated with plasma con-
centration, consistent with a competitive mechanism of
action. By contrast, κ antagonism is negatively correlated
with plasma concentrations, but positively correlated
with exposure. Both of these correlations are more con-
sistent with an irreversible mechanism of action such as
JNK1-mediated desensitization.
Our results indicate that JDTic is a P-gp substrate, but
that nor-BNI and GNTI are not. However, the extremely
low brain uptake of these drugs suggests that they may
be substrates of another transporter. Our findings that
these drugs are relatively hydrophilic by several mea-
sures suggest that they will not form a membrane depot.
Their modest affinities for brain homogenate also argue
against other forms of nonspecific tissue binding. JDTic’s
extremely slow elimination from brain, despite low affin-
ity for homogenate and active efflux, suggests intracellu-
lar trapping. We propose lysosomes as a plausible site
for this entrapment, but no direct evidence is yet avail-
able. JDTic’s persistence in brain may contribute to its
long duration of action, but this cannot account for its
ultra-slow onset, nor for the even longer duration of ac-
tion exhibited by nor-BNI.
Materials and methods
Animals Male Swiss-Webster mice (22–24 g, Crl:CFW
(SW), Charles River. Laboratories, Wilmington MA,
USA) were housed under a 12 h light/dark cycle in clear
polycarbonate boxes (three per box) with pine chip bed-
ding, nesting pads, and unrestricted food and water.
Experiments were performed between 10 am and 6 pm.
Mice were not used in other experiments, or exposed to
other drugs, before testing began. This study followed
the recommendations of the Institute for Laboratory
Animal Research [60], and has been reported according
to the ARRIVE guidelines [61]. The protocol was
approved by McLean Hospital Institutional Animal Care
and Use Committee (protocol 09-5/2-16)
Drugs GNTI∙2HCl∙1.5H2O: Tocris Bioscience, Ellisville
MI (batches 4B/91591 and 4B/94133, >99.4% purity).
GNTI∙2CF3CO2H∙2.6H2O: Sigma-Aldrich, St Louis MI
(lot 096 K4605, 97.6% purity). JDTic∙2HCl∙H2O: F. Ivy
Carroll, Research Triangle Institute, NC. Naltrexo-
ne∙HCl∙2H2O: Tocris Bioscience (batch 5B/93329). Nor-
BNI∙2HCl∙H2O: Tocris Bioscience (batches 8A/90732
and 9A/93084). Vincristine: Sigma-Aldrich, St Louis MI.
Other materials Medium 199 and heat-inactivated fetal
bovine serum (FBS): Invitrogen (Carlsbad, CA). Non-col-
lagen-coated transwell plates (0.4 μm pore size, 0.7 cm
2
surface area): Millipore Corporation (Billerica, MA). Bo-
vine serum albumin (BSA), ethylenediaminetetraacetic
acid (EDTA), 1-octanol and phosphate-buffered saline
(PBS, pH 7.4): Sigma-Aldrich, St Louis MI.
Drug administration Doses are reported by weight of
the specified salt. Intraperitoneal injections were admi-
nistered in distilled water vehicle (10 mL kg
-1). Body
mass was measured to ±0.1 g. Some values were inad-
vertently measured on a low-precision balance (± 2.5 g);
these timepoints were replicated at ±0.1 g. Comparison
of results from these replicates revealed no statistically
significant difference, so all results were pooled for
analysis.
Sample preparation Mice were sacrificed by cervical
dislocation, then decapitated for collection of brain and
blood samples. Trunk blood was collected in 1.5 mL
polypropylene micro-centrifuge tubes, shaken with a few
crystals of EDTA and cooled in ice-water. Samples were
centrifuged at 14,000 rpm (revolutions per minute) for
15 minutes at 3 °C, then stored in glass sample vials at
−20 °C until analysis. Brains were removed and immersed
for 30 seconds in 2-methylbutane over dry ice, then
stored in polypropylene tubes at −20 °C until sample
preparation. Sample tubes were thawed in ice-water, dis-
tilled water was added (2:1 by weight) and the brain
homogenized with a probe sonicator for 3 minutes over
ice-water (Fisher Sonic Dismembrator 300 at 35%
power). The probe was rinsed with ethanol and distilled
water between samples. Brain homogenate was stored in
glass sample vials at −20 °C until analysis by LC-MS-MS.
LLC-PK1-MDR1 cell permeation and efflux Pig kid-
ney epithelial cells (LLC-PK1) were obtained from
American Type Culture Collection (Manassas, VA).
Transfection with human MDR1 gene was conducted at
Amgen (Thousand Oaks, CA). Bi-directional permeation
assays were performed as described previously [62].
Briefly, cells were grown in Medium 199 supplemented
with 10% FBS in the presence of vincristine (640 nM).
Cells were seeded onto Transwell filter membranes
(0.4 μm pore size, surface area =0.7 cm2) at a density of
200,000 cells/well. Compound incubations (in duplicate)
were performed 5 days post-seeding. To determine ef-
flux, compounds were tested at 5 μM in the presence of
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a humidified incubator with shaking (70 rpm) for
120 min. Samples were analyzed by LC-MS-MS.
Octanol-buffer distribution Phosphate-buffered saline
(PBS, pH 7.4) and 1-octanol were mutually saturated by
vigorous stirring at room temperature for 18 h, and then
separated. Drug solutions of 0.1 mg mL
-1 in PBS were
prepared, and 500 μL aliquots were added to 1.5 mL
micro-centrifuge tubes with an equal volume of 1-octa-
nol. Three samples were vortex-mixed for 1, 10 and 30
minutes respectively, then centrifuged at room
temperature (12,000 rpm for 15 minutes). Aliquots of
the upper octanol layer were removed by pipette. A dis-
posable syringe was inserted while bubbling air through
the upper layer, an aliquot of the lower PBS layer with-
drawn, and the needle removed before transferring.
Samples were stored in glass sample vials at −20 °C until
analysis by LC-MS-MS. Since no trend was evident with
mixing time, results from the different mixing times
were pooled.
Water solubility Distilled water was added slowly by
microsyringe to 10–15 mg of drug in a glass vial, swir-
ling until no solid was visible.
Determination of drug concentrations Drug concen-
trations (ng mL
-1) refer to the free base, and were mea-
sured by liquid chromatography-tandem mass spectrometry
(LC-MS-MS) as described previously [24]. Briefly, samples
were shaken with 3 volumes of methanol and centrifuged at
3000 g. Aliquots of the supernatants were diluted with 5
volumes of water containing an appropriate internal stand-
ard. Extracts from in vitro and in vivo experiments were
analyzed by multiple reaction monitoring on an API3000 or
API4000 LC-MS-MS system with electrospray ion source,
controlled and analyzed using the Analyst software package
(Applied Biosystems, Foster City, CA). Chromatography
was conducted on a Sprite Armor C18 analytical column
(20 × 2.1 mm, 10 μm particle size, Analytical Sales and
Products, Pompton Plains, NJ) with a 0.5 μmP E E Kg u a r d
filter. Compounds were eluted with a gradient from 2% to
95% acetonitrile in water, both containing 0.1% formic
acid. Compounds were detected in positive ion mode,
tuned to the mass transition with the largest intensity.
Analyte concentrations were determined by comparison
of analyte:internal standard peak area ratios to those of
standards prepared in the appropriate matrices.
Brain homogenate and plasma binding Unbound frac-
tions in brain homogenate and plasma were determined
by ultracentrifugation as described previously [24].
Briefly, drug-spiked matrices (5 μM drug in plasma or
brain homogenate) were centrifuged at 600,000 g for 5 h
at 37 °C (plasma) or 5 °C (brain). Aliquots of the middle
(water) layer were added to an equal volume of blank
matrix and extracted with 5 volumes of acetonitrile con-
taining internal standard. Aliquots of the original spiked
matrix were mixed with an equal volume of blank
matrix and 2 volumes of plasma ultrafiltrate (plasma) or
phosphate-buffered saline (tissue) and extracted with 10
volumes of acetonitrile. Extracts were centrifuged and
analyzed by LC-MS-MS. Fraction unbound was calcu-
lated from the ratio of concentration in the water layer
to that in the original spiked matrix, corrected for dilu-
tion as described previously [24]. Based on previous
results for basic drugs, in vivo free fraction in brain was
assumed to be at least 3-fold lower than the in vitro free
fraction in brain homogenate [34].
Data analysis For calculation of mean concentrations,
the earliest values below the MRC were substituted by
MRC ÷ 2, as recommended elswhere [63]. Pharmacoki-
netic parameters were calculated from mean concentra-
tions using PKSolver [64], employing non-compartmental
analysis for extravascular administration. Curves in figures
were fitted using Origin 8.5 (OriginLab, Northampton,
MA) using 2-compartment models. Confidence intervals
and two-tailed p values (unpaired t test) were calculated
using Graphpad Quickcalcs [65]. One outlier was identi-
fied using Grubbs' test (p<0.01) and excluded from the
analysis; see Additional file 1.
Extraction of published data Where data were not
given in tables, values were extracted from graphs using
Engauge Digitizer [66].
Additional file
Additional file 1: Raw data for figures and tables as a Microsoft Excel
spreadsheet. Readable by free software including LibreOffice and Google
Docs.
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